Reverse remodeling in heart failure-mechanisms and therapeutic opportunities

Nature Reviews Cardiology

Volumn 9, Issue 3, 2012, Pages 147-157

  Koitabashi, Norimichi ^a   Kass, David A ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; G PROTEIN COUPLED RECEPTOR KINASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HYDRALAZINE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN S100A1; RUBOXISTAURIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SOTRASTAURIN; SPIRONOLACTONE; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CARDIAC RESYNCHRONIZATION THERAPY; CELL SURVIVAL; CELL THERAPY; DRUG MECHANISM; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE REMODELING; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC PACING, ARTIFICIAL; DISEASE PROGRESSION; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84857643399     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.172     Document Type: Review

References (143)

1. Lloyd-Jones, D. et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121, e46-e215 (2010).
2. Cohn, J. N., Ferrari, R. & Sharpe, N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35, 569-582 (2000). (Pubitemid 30167013)
3. Opie, L. H., Commerford, P. J., Gersh, B. J. & Pfeffer, M. A. Controversies in ventricular remodelling. Lancet 367, 356-367 (2006). (Pubitemid 43151469)
4. Kehat, I. & Molkentin, J. D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122, 2727-2735 (2010).
5. Mudd, J. O. & Kass, D. A. Reversing chronic remodeling in heart failure. Expert Rev. Cardiovasc. Ther. 5, 585-598 (2007). (Pubitemid 46805584)
6. Pfeffer, J. M., Pfeffer, M. A. & Braunwald, E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ. Res. 57, 84-95 (1985). (Pubitemid 15238844)
7. Gaasch, W. H. Left ventricular radius to wall thickness ratio. Am. J. Cardiol. 43, 1189-1194 (1979). (Pubitemid 9191003)
8. Esposito, G. et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85-92 (2002). (Pubitemid 34049147)
9. Perrino, C. et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560 (2006).
10. Devereux, R. B. et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110, 1456-1462 (2004). (Pubitemid 39238023)
11. Drazner, M. H. The progression of hypertensive heart disease. Circulation 123, 327-334 (2011).
12. Krishnamoorthy, A. et al. Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up. Am. J. Cardiol. 108, 997-1001 (2011).
13. Mudd, J. O. & Kass, D. A. Tackling heart failure in the twenty-first century. Nature 451, 919-928 (2008). (Pubitemid 351301747)
14. Kass, D. A. et al. Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation 91, 2314-2318 (1995).
15. Klotz, S. et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J. Am. Coll. Cardiol. 45, 668-676 (2005). (Pubitemid 40278964)
16. Dipla, K., Mattiello, J. A., Jeevanandam, V., Houser, S. R. & Margulies, K. B. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 97, 2316-2322 (1998). (Pubitemid 28280385)
17. Gray, M. O., Long, C. S., Kalinyak, J. E., Li, H. T. & Karliner, J. S. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF β1 and endothelin 1 from fibroblasts. Cardiovasc. Res. 40, 352-363 (1998). (Pubitemid 28506046)
18. Sharpe, N. et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet 337, 872-876 (1991).
19. Granger, C. B. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772-776 (2003). (Pubitemid 37093917)
20. 2+-dependent signaling. Circ. Res. 76, 1-15 (1995).
21. Habashi, J. P. et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332, 361-365 (2011).
22. Avila, M. D., Morgan, J. P. & Yan, X. Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure. J. Biomed. Biotechnol. 2011, 141039 (2011).
23. Solomon, S. D. et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111, 3411-3419 (2005). (Pubitemid 40923394)
24. Wittstein, I. S. et al. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilatedcardiomyopathy. J. Am. Coll. Cardiol. 38, 429-435 (2001). (Pubitemid 32721771)
25. Lonn, E. et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J. Am. Coll. Cardiol. 43, 2200-2206 (2004). (Pubitemid 38757585)
26. Ciulla, M. M. et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 110, 552-557 (2004). (Pubitemid 39031172)
27. Brilla, C. G., Zhou, G., Matsubara, L. & Weber, K. T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell Cardiol. 26, 809-820 (1994). (Pubitemid 24223231)
28. Yoshida, M. et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest. Heart Fail. 11, 12-16 (2005).
29. Fraccarollo, D. et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. 42, 1666-1673 (2003). (Pubitemid 37378451)
30. Veliotes, D. G. et al. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by β-adrenoreceptor activation. Hypertension 45, 914-920 (2005). (Pubitemid 40628937)
31. Hayashi, M. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559-2565 (2003). (Pubitemid 36628936)
32. Udelson, J. E. et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild to moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 3, 347-353 (2010).
33. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003). (Pubitemid 36384098)
34. Solomon, S. D. et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32, 1227-1234 (2011).
35. Mann, D. L., Kent, R. L., Parsons, B. & Cooper, G. 4th. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85, 790-804 (1992).
36. Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M. J. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc. Natl Acad. Sci. USA 96, 7059-7064 (1999). (Pubitemid 29275009)
37. Lowes, B. D. et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346, 1357-1365 (2002). (Pubitemid 34754608)
38. Reiken, S. et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107, 2459-2466 (2003). (Pubitemid 36605229)
39. Bohm, M., Deutsch, H. J., Hartmann, D., Rosee, K. L. & Stablein, A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J. Am. Coll. Cardiol. 30, 992-996 (1997). (Pubitemid 27435892)
40. Beanlands, R. S. et al. The effects of β1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 102, 2070-2075 (2000).
41. Baldasseroni, S. et al. Left bundle-branch block is associated with increased 1 year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am. Heart J. 143, 398-405 (2002). (Pubitemid 34185169)
42. Prinzen, F. W., Hunter, W. C., Wyman, B. T. & McVeigh, E. R. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. J. Am. Coll. Cardiol. 33, 1735-1742 (1999).
43. Spragg, D. D. & Kass, D. A. Pathobiology of left ventricular dyssynchrony and resynchronization. Prog. Cardiovasc. Dis. 49, 26-41 (2006). (Pubitemid 44080800)
44. van Oosterhout, M. F., Arts, T., Bassingthwaighte, J. B., Reneman, R. S. & Prinzen, F. W. Relation between local myocardial growth and blood flow during chronic ventricular pacing. Cardiovasc. Res. 53, 831-840 (2002). (Pubitemid 34261021)
45. Nelson, G. S. et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102, 3053-3059 (2000).
46. Yu, C. M. et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105, 438-445 (2002).
47. Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140-2150 (2004).
48. Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539-1549 (2005). (Pubitemid 40517094)
49. Chakir, K. & Kass, D. A. Rethinking resynch: exploring mechanisms of cardiac resynchroniztion beyond wall motion control. Drug Discov. Today Dis. Mech. 7, e103-e107 (2010).
50. Chakir, K. et al. Gas-biased β2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci. Transl. Med. 3, 100ra88 (2011).
51. Aiba, T. et al. Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation 119, 1220-1230 (2009).
52. Barth, A. S. et al. Cardiac resynchronization therapy corrects dyssynchrony-induced regional gene expression changes on a genomic level. Circ. Cardiovasc. Genet. 2, 371-378 (2009).
53. Wang, S. B. et al. Redox regulation of mitochondrial ATP synthase: implications for cardiac resynchronization therapy. Circ. Res. 109, 750-757 (2011).
54. Zafeiridis, A., Jeevanandam, V., Houser, S. R. & Margulies, K. B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98, 656-662 (1998). (Pubitemid 28387492)
55. Delgado, R. 3rd, Radovancevic, B., Massin, E. K., Frazier, O. H. & Benedict, C. Neurohormonal changes after implantation of a left ventricular assist system. ASAIO J. 44, 299-302 (1998). (Pubitemid 28328744)
56. Barbone, A. et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 104, 670-675 (2001). (Pubitemid 32738521)
57. Anand, I. et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364, 347-354 (2004).
58. 2+ cycling after left ventricular assist device support in the failing human heart. J. Am. Coll. Cardiol. 44, 837-845 (2004). (Pubitemid 39099582)
59. Terracciano, C. M. et al. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 109, 2263-2265 (2004). (Pubitemid 38656863)
60. Drakos, S. G. et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J. Am. Coll. Cardiol. 56, 382-391 (2010).
61. Sandritter, W. & Adler, C. P. Polyploidization of heart muscle nuclei as a prerequisite for heart growth and numerical hyperplasia in heart hypertrophy. Recent Adv. Stud. Cardiac. Struct. Metab. 12, 115-127 (1976).
62. Wohlschlaeger, J. et al. Hemodynamic support by left ventricular assist devices reduces cardiomyocyte DNA content in the failing human heart. Circulation 121, 989-996 (2010).
63. Soppa, G. K. et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am. J. Physiol. Heart Circ. Physiol. 288, H1468-H1476 (2005). (Pubitemid 40270059)
64. Birks, E. J. et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med. 355, 1873-1884 (2006). (Pubitemid 44664645)
65. Birks, E. J. et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 123, 381-390 (2011).
66. Wollert, K. C. & Drexler, H. Clinical applications of stem cells for the heart. Circ. Res. 96, 151-163 (2005). (Pubitemid 40209362)
67. Schachinger, V. et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210-1221 (2006). (Pubitemid 44427445)
68. Williams, A. R. et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ. Res. 108, 792-796 (2011).
69. Lee, S. T. et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J. Am. Coll. Cardiol. 57, 455-465 (2011).
70. Abdel-Latif, A. et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 167, 989-997 (2007). (Pubitemid 46835786)
71. Mirotsou, M., Jayawardena, T. M., Schmeckpeper, J., Gnecchi, M. & Dzau, V. J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J. Mol. Cell Cardiol. 50, 280-289 (2011).
72. Münzel, T. et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 98, 1465-1470 (1996). (Pubitemid 26322073)
73. Cohn, J. N. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314, 1547-1552 (1986). (Pubitemid 16114684)
74. Cohn, J. N. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
75. Taylor, A. L. et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049-2057 (2004).
76. Batista, R. J. et al. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J. Card. Surg. 11, 96-97 (1996). (Pubitemid 126426092)
77. Starling, R. C. et al. Results of partial left ventriculectomy for dilated cardiomyopathy: hemodynamic, clinical and echocardiographic observations. J. Am. Coll. Cardiol. 36, 2098-2103 (2000).
78. Athanasuleas, C. L. et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J. Am. Coll. Cardiol. 44, 1439-1445 (2004). (Pubitemid 39303946)
79. Jones, R. H. et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J. Med. 360, 1705-1717 (2009).
80. Cohn, J. N. Pharmacotherapy: inhibiting LV remodeling-the need for a targeted approach. Nat. Rev. Cardiol. 8, 248-249 (2011).
81. Krum, H. et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Fail. 13, 1-7 (2007). (Pubitemid 46330836)
82. Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004). (Pubitemid 38451714)
83. 2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442 (1994).
84. Kawase, Y. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119 (2008). (Pubitemid 351374774)
85. Sakata, S. et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J. Mol. Cell Cardiol. 42, 852-861 (2007). (Pubitemid 46527593)
86. Byrne, M. J. et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 15, 1550-1557 (2008).
87. Jaski, B. E. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first in human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181 (2009).
88. 2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313 (2011).
89. Kho, C. et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477, 601-605 (2011).
90. Tsai, E. J. & Kass, D. A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 122, 216-238 (2009).
91. Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11, 214-222 (2005). (Pubitemid 40321358)
92. Nagayama, T. et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol. 53, 207-215 (2009).
93. 2+/calmodulin-dependent protein kinase IId and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ. Res. 102, 695-702 (2008). (Pubitemid 351457864)
94. Backs, J., Song, K., Bezprozvannaya, S., Chang, S. & Olson, E. N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 116, 1853-1864 (2006). (Pubitemid 44033310)
95. 2+ handling but exacerbates cardiac dysfunction in CaMKIIdc transgenic mice. Circ. Res. 106, 354-362 (2010).
96. Guazzi, M., Vicenzi, M., Arena, R. & Guazzi, M. D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1 year, prospective, randomized, placebo-controlled study. Circ. Heart Fail. 4, 8-17 (2011).
97. US National Library of Medicine. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study). ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT00763867 (2011).
98. Bristow, M. R. et al. Decreased catecholamine sensitivity and β adrenergic receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211 (1982). (Pubitemid 12079105)
99. Lymperopoulos, A., Rengo, G. & Koch, W. J. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13, 503-511 (2007). (Pubitemid 350123195)
100. Choi, D. J., Koch, W. J., Hunter, J. J. & Rockman, H. A. Mechanism of β adrenergic receptor desensitization in cardiac hypertrophy is increased β adrenergic receptor kinase. J. Biol. Chem. 272, 17223-17229 (1997). (Pubitemid 27289837)
101. Iaccarino, G. et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26, 1752-1758 (2005). (Pubitemid 41219848)
102. Inglese, J., Freedman, N. J., Koch, W. J. & Lefkowitz, R. J. Structure and mechanism of the G protein-coupled receptor kinases.J. Biol. Chem. 268, 23735-23738 (1993). (Pubitemid 23335333)
103. Koch, W. J. et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 268, 1350-1353 (1995).
104. Raake, P. W. et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res. 103, 413-422 (2008).
105. Rengo, G. et al. Myocardial adeno-associated virus serotype 6 βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119, 89-98 (2009).
106. Volkers, M. et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 41, 135-143 (2007). (Pubitemid 46014745)
107. 2+-ATPase2a and phospholamban in the human heart. Biochem. Biophys. Res. Commun. 306, 550-557 (2003). (Pubitemid 36683110)
108. Yamasaki, R. et al. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys. J. 81, 2297-2313 (2001). (Pubitemid 32917177)
109. 2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol. Cell. Biol. 27, 4365-4373 (2007). (Pubitemid 46906561)
110. Rohde, D. et al. S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials. J. Mol. Cell. Cardiol. 50, 777-784 (2011).
111. Noma, T. et al. β Arrestin mediated β1 adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458 (2007).
112. Pleger, S. T. et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115, 2506-2515 (2007). (Pubitemid 46763224)
113. Most, P. et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J. Clin. Invest. 114, 1550-1563 (2004). (Pubitemid 40385546)
114. Pleger, S. T. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3, 92ra64 (2011).
115. Crockford, D., Turjman, N., Allan, C. & Angel, J. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Ann. N. Y. Acad. Sci. 1194, 179-189 (2010).
116. Takimoto, E. et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119, 408-420 (2009).
117. Tokudome, T. et al. Regulator of G protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 117, 2329-2339 (2008). (Pubitemid 351653552)
118. Koitabashi, N. et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J. Mol. Cell. Cardiol. 48, 713-724 (2010).
119. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M. & Srivastava, D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432, 466-472 (2004). (Pubitemid 39576522)
120. Zhou, B. et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454, 109-113 (2008). (Pubitemid 351931979)
121. Smart, N. et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 474, 640-644 (2011).
122. US National Library of Medicine. A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01311518 (2011).
123. Anderson, M. E., Brown, J. H. & Bers, D. M. CaMKII in myocardial hypertrophy and heart failure. J. Mol. Cell. Cardiol. 51, 468-473 (2011).
124. Khoo, M. S. et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 114, 1352-1359 (2006). (Pubitemid 44454555)
125. Churchill, E., Budas, G., Vallentin, A., Koyanagi, T. & Mochly-Rosen, D. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu. Rev. Pharmacol. Toxicol. 48, 569-599 (2008). (Pubitemid 351738164)
126. 2+-sensitive isoforms in the failing human heart. Circulation 99, 384-391 (1999). (Pubitemid 29051264)
127. Braz, J. C. et al. PKC-a regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248-254 (2004). (Pubitemid 38667614)
128. Liu, Q. & Molkentin, J. D. Protein kinase Ca as a heart failure therapeutic target. J. Mol. Cell. Cardiol. 51, 474-478 (2010).
129. Malhotra, R. et al. Gaq-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. J. Biol. Chem. 285, 13748-13760 (2010).
130. Hahn, H. S. et al. Protein kinase Ca negatively regulates systolic and diastolic function in pathological hypertrophy. Circ. Res. 93, 1111-1119 (2003). (Pubitemid 37485043)
131. Liu, Q. et al. Protein kinase Ca, but not PKCβ or PKC?, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ. Res. 105, 194-200 (2009).
132. Boyle, A. J. et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J. Mol. Cell. Cardiol. 39, 213-221 (2005). (Pubitemid 40995010)
133. PKC DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 125, 318-324 (2007).
134. PKC DRS2 Group et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113, 2221-2230 (2006).
135. Berry, J. M. et al. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ. Res. 109, 407-417 (2011).
136. Rowell, J., Koitabashi, N. & Kass, D. A. TRP-ing up heart and vessels: canonical transient receptor potential channels and cardiovascular disease. J. Cardiovasc. Transl. Res. 3, 516-524 (2010).
137. Jugdutt, B. I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108, 1395-1403 (2003). (Pubitemid 37174420)
138. Lindsey, M. L. et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105, 753-758 (2002). (Pubitemid 34157381)
139. Hudson, M. P. et al. Effects of selective matrix metalloproteinase inhibitor (PG 116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. 48, 15-20 (2006). (Pubitemid 43929218)
140. Creemers, E. E. & Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 89, 265-272 (2011).
141. Koitabashi, N. et al. Pivotal role of cardiomyocyte TGF β signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301-2312 (2011).
142. Udelson, J. E. et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am. Heart J. 139, 503-510 (2000). (Pubitemid 30149201)
143. Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007). (Pubitemid 350190755)